Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE5A | O76074 | 19/20 | 1.00 |
| ▸ | PDE6C | P51160 | 3/20 | 1.00 |
| ▸ | HDAC1 | Q13547 | 9/20 | 0.64 |
| ▸ | HDAC6 | Q9UBN7 | 8/20 | 0.64 |
| ▸ | HDAC2 | Q92769 | 7/20 | 0.64 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.62 |
| ▸ | NCOR2 | Q9Y618 | 1/20 | 0.62 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.60 |
| ▸ | PDE1A | P54750 | 2/20 | 0.60 |
| ▸ | PDE1B | Q01064 | 2/20 | 0.60 |
| ▸ | PDE1C | Q14123 | 2/20 | 0.60 |
| ▸ | MEN1 | O00255 | 1/20 | 0.60 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.60 |
| ▸ | HPGD | P15428 | 1/20 | 0.60 |
| ▸ | PDE3B | Q13370 | 3/20 | 0.60 |
| ▸ | PDE3A | Q14432 | 3/20 | 0.60 |
| ▸ | PDE2A | O00408 | 1/20 | 0.59 |
| ▸ | ABCC4 | O15439 | 1/20 | 0.59 |
| ▸ | ABCC5 | O15440 | 1/20 | 0.59 |
| ▸ | PDE6D | O43924 | 1/20 | 0.59 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL146830 | 0.95 | PDE5A (0.90) | PDE5APDE6CHDAC1HDAC6HDAC2 | |
| SCHEMBL29611957 | 0.95 | PDE5A (0.90) | PDE5APDE6CHDAC1HDAC6HDAC2 | |
| SCHEMBL25013469 | 0.92 | PDE5A (0.85) | PDE5APDE6CHDAC1HDAC6HDAC2 | |
| SCHEMBL29357402 | 0.92 | PDE5A (0.85) | PDE5APDE6CHDAC1HDAC6HDAC2 | |
| SCHEMBL7964961 | 0.92 | PDE5A (0.85) | PDE5APDE6CHDAC1HDAC6HDAC2 | |
| SCHEMBL30199753 | 0.92 | PDE5A (0.85) | PDE5APDE6CHDAC1HDAC6HDAC2 | |
| SCHEMBL2693448 | 0.92 | PDE5A (0.85) | PDE5APDE6CHDAC1HDAC6HDAC2 | |
| SCHEMBL6367349 | 0.92 | PDE5A (0.84) | PDE5APDE6CHDAC1HDAC6HDAC2 | |
| SCHEMBL7965731 | 0.92 | PDE5A (0.84) | PDE5APDE6CHDAC1HDAC6HDAC2 | |
| SCHEMBL28482244 | 0.91 | PDE5A (0.83) | PDE5APDE6CHDAC1HDAC6HDAC2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 364 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20180036314-A1 | METHODS AND COMPOSITIONS FOR TREATING PERIPHERAL VASCULAR DISEASE | EXODOS LIFE SCIENCES LP (US) | 2018-02-08 | — | — | US | claimed |
| US-20150031704-A1 | METHODS AND COMPOSITIONS FOR TREATING PERIPHERAL VASCULAR DISEASE | EXODOS LIFE SCIENCES LIMITED PARTNERSHIP | 2015-01-29 | — | — | US | claimed |
| US-20130053393-A1 | METHODS AND COMPOSITIONS FOR TREATING PERIPHERAL VASCULAR DISEASE | EXODOS LIFE SCIENCES LIMITED PARTNERSHIP (US) | 2013-02-28 | — | — | US | claimed |
| EP-2512479-A1 | METHODS AND COMPOSITIONS FOR TREATING PERIPHERAL VASCULAR DISEASE | Exodos Life Sciences Limited Partnership (US) | 2012-10-24 | — | — | EP | claimed |
| WO-2011075655-A1 | METHODS AND COMPOSITIONS FOR TREATING PERIPHERAL VASCULAR DISEASE | EXODOS LIFE SCIENCES LIMITED PARTNERSHIP (US) | 2011-06-23 | — | — | WO | claimed |
| US-20080051408-A1 | Use of a Pde 5 Inhibitor for Treating and Preventing Hypopigmentary Disorders | SWITCH BIOTECH, LLC | 2008-02-28 | — | — | US | claimed |
| EP-1759700-A1 | Use of a PDE5 inhibitor for treating and preventing hypopigmentary disorders | Switch Biotech Aktiengesellschaft (DE) | 2007-03-07 | — | — | EP | claimed |
| US-20060041014-A1 | Treatment of male sexual dysfunction | PFIZER INC | 2006-02-23 | — | — | US | claimed |
| US-20040167095-A1 | Use of PDE V inhibitors for improved fecundity in mammals | WESTBROOK SIMON LEMPRIERE (GB) | 2004-08-26 | — | — | US | claimed |
| US-20030144296-A1 | Daily treatment for erectile dysfunction using a PDE5 inhibitor | LILLY ICOS LLC | 2003-07-31 | — | — | US | claimed |
| EP-1199070-A2 | Use of PDE V inhibitors for improved fecundity in mammals | Pfizer Limited (GB) | 2002-04-24 | — | — | EP | claimed |
| US-20020028799-A1 | Treatment of male sexual dysfunction | PFIZER INC. | 2002-03-07 | — | — | US | claimed |
| US-20010053780-A1 | Daily treatment for erectile dysfunction using a PDE5 inhibitor | LILLY ICOS LLC, A DELAWARE CORPORATION | 2001-12-20 | — | — | US | claimed |
| EP-1157705-A2 | Use of a phosphodiesterase inhibitor in the manufacture of a medicament for blood pressure stabilization during hemodialysis | Pfizer Products Inc. (US) | 2001-11-28 | — | — | EP | claimed |
| US-6271228-B1 | ADMINISTERING PHOSPHODIESTERASE INHIBITOR | PFIZER INC. | 2001-08-07 | — | — | US | claimed |
| US-6225315-B1 | ADMINISTERING A CGMP PDE INHIBITOR. | PFIZER INC | 2001-05-01 | — | — | US | claimed |
| EP-1022026-A2 | Pharmaceutical compositions for treating nitrate-induced tolerance | Pfizer Limited (GB) | 2000-07-26 | — | — | EP | claimed |
| EP-0702555-B1 | PYRAZOLOPYRIMIDINONES FOR THE TREATMENT OF IMPOTENCE | PFIZER LTD (GB) | 1998-03-11 | — | — | EP | claimed |
| EP-0526004-B1 | Pyrazolopyrimidinone antianginal agents | PFIZER LTD (GB) | 1997-10-08 | — | — | EP | claimed |
| EP-0526004-A1 | Pyrazolopyrimidinone antianginal agents | Pfizer Limited (GB) | 1993-02-03 | — | — | EP | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060041014-A1 | Treatment of male sexual dysfunction | MME, PDE5A, PREP | PDE5A 2/4885PDE6C 91/4885HDAC1 1731/4885 |
| US-20040167095-A1 | Use of PDE V inhibitors for improved fecundity in mammals | PDE5A, PDE2A, PDE3A | PDE5A 1/4885PDE6C 18/4885HDAC1 643/4885 |
| US-20020028799-A1 | Treatment of male sexual dysfunction | MME, PDE5A, PREP | PDE5A 2/4885PDE6C 91/4885HDAC1 1731/4885 |
| US-20030144296-A1 | Daily treatment for erectile dysfunction using a PDE5 inhibitor | PDE5A, PDE3A, PDE2A | PDE5A 1/4885PDE6C 18/4885HDAC1 1237/4885 |
| US-20010053780-A1 | Daily treatment for erectile dysfunction using a PDE5 inhibitor | PDE5A, PDE3A, PDE2A | PDE5A 1/4885PDE6C 16/4885HDAC1 1617/4885 |
| US-20080051408-A1 | Use of a Pde 5 Inhibitor for Treating and Preventing Hypopigmentary Disorders | PDE5A, PDE2A, PDE3A | PDE5A 1/4885PDE6C 8/4885HDAC1 171/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.